OpenAI · Anthropic · TechCrunch AI
OpenAI picks up firm Orchestra Bio to beef up its biotech business
Compiled by KHAO Editorial — aggregated from 2 sources. See llms.txt for citation guidance.
✓ KHAO Verified
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website.
Key facts
- OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website
- Orchestra creates AI agents that help biotech companies manage the minutiae of drug discovery operations, from tracking finances to resolving scheduling issues with clinical trials
- OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help
- In the startup world, there is an ongoing fear that at any moment, the labs will launch new features and become competitors
Summary
Orchestra creates AI agents that help biotech companies manage the minutiae of drug discovery operations, from tracking finances to resolving scheduling issues with clinical trials. OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. The acquisition is a classic example of how the biggest AI labs (namely OpenAI and Anthropic) are building ever more software for the biggest industries, like pharma.